The Company

Global Life Technologies Corp. (GLT) is the maker of the NOZIN® brand products. The Company formed with the mission to improve the quality of life for people by introducing unique and effective healthcare products. Our Company motto is to “enhance life through innovative health technologies”. The Company intends to fulfill its mission through the development, marketing and sales of superior healthcare products throughout the world.

Our proprietary products are directed at the growing health maintenance and disease prevention markets. The NOZIN® Nasal Sanitizer® antiseptic, the Company’s first product under the NOZIN® brand, is supported by substantial research, development and successful clinical trials (see below). Nozin focuses on products that help the nose optimize its natural function to protect and enhance our well being. We are all primarily nose breathers which makes the nose our body's vital connection to the environment. For Nozin, "Healthy Nose, Healthy Life™" is our guiding principle which highlights how important the nose is to our body's health and our lives.

Scientific Steering Committee and Advisory Board

We are committed to continuing our investments in research and have enlisted the support of the scientific community by forming a Scientific Steering Committee composed of prominent scientists from major research universities in the United States. The scientists on this committee are all independently funded by the National Institutes of Health to carry out research in areas related to transmission of infectious diseases. The Steering Committee has, in turn, identified and recruited independent scientists who are recognized as the leading experts in the area of airborne diseases to carry out the studies that validate the efficacy of Nozin. Validation and support from renowned physicians and researchers is central to our aim of providing quality health products to consumers.

Dr. Richard Markham (Bio), the Chairman of GLT’s Scientific Steering Committee, a Medical Doctor and renowned infectious disease specialist, is known for his groundbreaking work in the area of novel microbicides, an area that GLT is actively pursuing. Another Advisor to the Board, Dr. Xiao-Fang Yu (Bio). Dr. Xiao-Fang Yu, a Chinese native, published an article in Science that bolstered his reputation for innovation in creating a vaccine for AIDS. A multi-site vaccine trial using Dr. Xiao-Fang Yu’s technology is underway in China at the present.

These experts, and others, are actively contributing to the scientific direction of the Company.

The Steering Committee looks at disease prevention

By Dr. Richard Markham, Committee Chairman

The members of the Scientific Steering Committee are academic scientists and physicians who are committed to the field of Public Health. This means that much of their research has focused on the issue of disease prevention, as opposed to disease treatment. Disease prevention is an area that, in the past, has received less attention from the medical community. Most physicians, after all, are trained to treat patients who come to them with an illness. But as the costs of medical treatment continue to climb and as those in the developed world, who can afford medical treatment, are increasingly exposed to those in the less developed world, who cannot afford medical treatment, it has become clear that simpler approaches, which make disease prevention accessible to all individuals, must be developed.

One approach that has proved useful is the development of antiseptics such as alcohol-based hand sanitizers. But for many infections the hands serve only as the vehicle that carries germs to the site where infection is actually initiated and introduced into the body, such as the eyes, mouth and especially the nose. It is this concept of attacking infections at the site where the disease process actually begins that attracted the scientists who are members or advisors of the GLT Scientific Steering Committee. It is the scientists' goal to use rigorous scientific analysis to ensure that products such as NOZIN® Nasal Sanitizer® antiseptic are the most effective they can possibly be.

Research

Contributing Labs

Extensive studies were undertaken to demonstrate that NOZIN® Nasal Sanitizer® antiseptic is a safe, highly effective anti-microbial that provides long lasting action to help reduce the risk of infection. These studies were conducted at leading independent US testing centers specializing in antimicrobial and personal care product testing with results interpretation.  All studies are statistically designed using Good Laboratory Practices (GLPs) to ensure FDA/EPA regulatory compliance and market success. The following are some of the results from these tests.

Nozin kills germs in lab tests

Summary: In laboratory tests conducted at several leading, FDA recognized testing facilities, and under GLP testing protocols, NOZIN® Nasal Sanitizer® antiseptic was effective in killing at least 99.99% of bacterial pathogens such as staph aureus, strep pneumoniae, strep pyogenes, mycobacterium smegmatis, and 99.9% of various pathogenic virus including rhinovirus type-14 (often responsible for the common cold), human coronavirus (responsible for the deadly SARS outbreak) and influenza type-A (influenza contracted by humans and birds).

Summary: While it is difficult to simulate the varied conditions of the human nose in an in-vitro model, there are surrogate tests that have been developed to help simulate these conditions. One such surrogate study is the use of a biofilm to help model in-vivo conditions.

This study examined the ability of NOZIN® Nasal Sanitizer® antiseptic to inhibit the growth of bacteria in biofilms over a period of up to 8 hours. Staphylococcus aureus, the challenge strain selected for the experiment and a pathogen commonly found to colonize the nares of healthcare personnel, was challenged with four test materials.

Results: Compared to control treatments, NOZIN® Nasal Sanitizer® antiseptic substantially reduced the bacterial growth even in the protective environment of the biofilm.

[Back to top]

Nozin controls germs for hours in human subjects

Summary: The effect of NOZIN® Nasal Sanitizer® antiseptic on the growth of bacteria in the nose was tested by applying Nozin or a control reagent to the noses of 30 subjects. The number of bacteria recovered from the nose was then determined over a 12 hour period following the application. The number of bacteria recovered from the group treated with NOZIN® Nasal Sanitizer® antiseptic was reduced by 90% compared to the control-treated group.

Results: Nozin inhibits the growth of bacteria in the nose and this effect lasts for up to 12 hours.

Nozin is shown to be safe in dermal toxicity and skin irritation study

Summary: NOZIN® Nasal Sanitizer® antiseptic was tested in human subjects to determine whether it could induce direct toxic effects to the skin or whether it could stimulate the development of allergic responses.  To test the toxic effect, NOZIN® Nasal Sanitizer® antiseptic was applied to a single location on the skin of the subjects once daily for 21 days.  It’s ability to produce toxic effects was compared to a 0.1% solution of Sodium Lauryl Sulfate, a common ingredient in soaps, shampoos, and other skin and hair care products.  After a rest period of 2 weeks, NOZIN® Nasal Sanitizer® antiseptic was reapplied to see if an allergic response had developed. 

Results: Compared to the commonly used Sodium Lauryl Sulfate, there was no evidence of toxicity or allergic responses induced by NOZIN® Nasal Sanitizer® antiseptic. Subjects did not become sensitized to NOZIN® Nasal Sanitizer® antiseptic and none of the subjects experienced an increase in skin irritation up to seventy-two (72) hours following the challenge exposure of three (3) weeks.

[Back to top]

NOZIN® Nasal Sanitizer®: Defense that makes sense

NOZIN® Nasal Sanitizer® antiseptic is an innovative, patent pending product that benefits consumers by providing extra protection against germs. In the past decade, hand sanitizers have become recognized and popularly used to deter transmission of germs. Because hand-to-nose contact is an important mechanism for the transmission infection, it can be beneficial to sanitize the skin on the nose as well as on the hands.

NOZIN® Nasal Sanitizer® antiseptic is specially formulated for the vulnerable and sensitive skin at the distal area of the nose and helps control germ populations that come to reside there. Lab tests show that NOZIN® Nasal Sanitizer® antiseptic kills harmful germs. Human trial results show that one application of NOZIN® Nasal Sanitizer® antiseptic can be effective for over eight hours (see above test summaries and results).

Unlike many existing products that purport to offer protection, NOZIN® Nasal Sanitizer® antiseptic is unique in that it attacks germs at the nose where most infections can occur. The Center for Disease Control already heavily promotes the importance of frequent hand washing and of hand sanitizers in helping prevent germs residing on hands from being transmitted to the nose. NOZIN® Nasal Sanitizer® antiseptic is longer lasting than many hand sanitizers and directly targets the chief area of infection, the nose. NOZIN® Nasal Sanitizer® antiseptic adds a targeted, long-acting level of defense by helping to shield your nose from hand-borne or airborne germs. Regular use of NOZIN® Nasal Sanitizer® antiseptic in conjunction with hand washing could provide a very effective hygienic regimen which can help reduce the risk of infection.

Many top physicians and scientists realize the compelling logic of hygienic innovation that NOZIN offers.  NOZIN® Nasal Sanitizer® antiseptic is a professionally valued and sensible approach in the effort to reduce the risk of infection.

Significance of NOZIN

The role of direct contact with hand contamination in the spread of colds was examined in a study in which iodine was used as a virucidal agent. In this study, the incidence of common colds was reduced by 40% in mothers who were treating their hands with iodine compared to mothers who used a placebo. While iodine may not have a preferred safety profile, this study suggested that an effective antiseptic that had residual activity on the hands for 2 to 3 hours could have an important impact on the spread of colds in the natural setting.

Our studies suggest that the active ingredients in NOZIN® Nasal Sanitizer® antiseptic are safe and have substantial activity against a wide variety of pathogenic organisms. Nozin Nasal Sanitizer has activity that persists for hours after application.

We believe that the observation that NOZIN® Nasal Sanitizer® antiseptic persists for hours after application at the site of potential infection has important implications to help reduce risk of germs. In light of the ubiquitous occurrence and medically important consequences of infections by harmful germs, and the evidence that a topical antiseptic can be beneficial, this simple and safe intervention could be an effective aid in the reduction of infections.

The toll of sickness

In the course of a year, individuals in the United States suffer 1 billion colds. It is estimated that each year Americans average at least three bouts of a cold or flu. The impact of such sickness is enormous. The National Center for Health Statistics (NCHS) estimated that, in 1998, 66 million cases of the common cold in the United States required medical attention or resulted in restricted activity. According to a 2003 study by the University of Michigan Health System, colds cause nearly 400 million missed work and school days each year at a cost of $20 billion. Additionally, more than $1.1 billion is spent annually on the estimated 41 million antibiotic prescriptions for colds, even though antibiotics have no effect on a virus but do contribute to the problem of antibiotic resistance by bacteria.

The high level of interest in the spread of disease is reflected in frequent, popular news reports on real and potential disease outbreaks. News about SARS, the potential for new, dangerous strains of influenza and shortages in flu vaccines have raised awareness of the vital import of better preventative measures.

According to the US Census Bureau there were 630 million US airplane passengers in 2003. Several studies indicate an increased risk of infection for passengers where 1 in 5 may get sick. Travelers may have good reason to associate contraction of illness with prolonged exposure to confined areas such as crowded airplane cabins. Learn more facts about the risk of infection.

Conclusion: Benefits of using Nozin® Nasal Sanitizer®

Many consumers are aware that every time they are in a crowded plane, bus, train, or in other settings where people congregate, they are exposed to germs and, therefore, more susceptible to illness. People are seeking ways of better protecting themselves. The products that do exist and are available for sale (vitamins, facemasks, hand sanitizers) are limited in their function. Other medicines used, such as antibiotics, are not broad spectrum or recommended for repeated use.

Better health and enhanced lifestyle can be key benefits of adopting a sound hygienic routine. Consumers who adopt and commit to a low-cost and effective hygienic regimen need to know they are doing something to help ensure their health and improve their quality of life. Less sick time on or off the job means more productivity and well-being at work and at leisure.

Top physicians and scientists realize that the hygienic benefits NOZIN® Nasal Sanitizer® antiseptic offers could provide critical first line defense in high risk, crowded or confined areas (e.g. airplanes, offices, schools, theaters, etc). NOZIN® Nasal Sanitizer® antiseptic can help reduce the risk of infection as an important part of health maintenance and in the fight against germ transmission.

Independent Research:

Read excerpts from medical reports on germ transmission here.

[Back to top]